drugset / Trial / NCT01060384
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2
Completed
46 enrolled
University of Nebraska
Celgene Corporation · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to investigate the efficacy (how well the drug works) of ofatumumab and lenalidomide in patients with lymphoma and to investigate if any possible unwanted side effects may occur. The purpose of the Phase I portion of this trial will be to determine the maximum dose of these medications that can be given with minimal side effects.
Timeline
- Start
- 2010-03-29
- Primary completion
- 2016-10-25
- Completion
- 2018-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Ofatumumab | Monoclonal antibody | 1000 mg | — |